APAC / How Precision Medicine is Transforming the Oncology Landscape
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer…
Top Stories
Moderna / Bullish Bancel “Not Losing Sleep” over COVID-19 Vaccine IP Waiver, Looking to mRNA’s Future in Rare Diseases & Oncology
The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However,…
Turkey / Koçak Farma & The Push for Homegrown COVID-19 Vaccines
As the international community continues its quest to vaccinate the global population against COVID-19, shortages…
Argentina / Politics and Pharma M&A
The COVID-19 pandemic has caused economic and social disruption and affected the behaviour of both consumers and…
APAC / Top Pharma Markets Ranking
The Top 10 pharma markets in the vast Asia-Pacific region, ranked by market size in USD millions for 2018. China is…
Canada / Top 10 Pharma Companies 2020 Ranking
The Top 10 companies in the Canadian pharma market for 2020, ranked by revenues in USD billions. J&J takes the…
Switzerland / Lonza Goes Big with Investments in Biologics, ADCs & Vaccines Manufacturing
In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in…
In Conversation
Guillermo Frydman – Managing Director, J&J Singapore
J&J Singapore’s Guillermo Frydman outlines how his affiliate negotiated the COVID-19 pandemic; why managing J&J’s pharma, medical devices, vision care and consumer businesses together offers unique opportunities to engage as a ‘broad healthcare company’; and Singapore’s role as an innovation hub for the region. There are many learnings on every front from the situation we went through last year.…
Latest Reports
Focus on USA
Moderna: Bullish Bancel “Not Losing Sleep” over COVID-19…
The day the Biden administration announced its support for the waiver of IP…
USA: 2 Things the Biden Administration can do Now to Lower…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can…
Mexico-US Vaccine Tourism: Closed Borders, Fear of Fakes…
While Mexico struggles with its COVID-19 vaccination campaign, residents of the…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading…
Read more: USA >>
Focus on China
China: EpimAb Looks to 2022 IPO & Global Leadership in…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb…
Boehringer Ingelheim’s Stroke Rehab Centre Success…
In March 2018, German pharma player Boehringer Ingelheim (BI)'s Consanas…
Public Insurance Coverage for Rare Disease Patients in…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare…
China Pharma News: Antitrust Threat to Pharma; June BioNTech…
The latest China pharma news, including the upcoming first domestic approval for…
Read more: China >>
Focus on Singapore
Medtech’s Post-COVID Paradigm in APAC
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech…
APAC: Diagnostics in the Post-COVID Era
COVID-19 has pushed diagnostics to the forefront of healthcare conversations…
Singapore: Finding the Right Pharma Talent Post-COVID
Singapore – despite its modest USD 1.22 billion domestic market – has long…
The Challenges of Regulatory Convergence in APAC Medtech
Regulatory harmonisation for medical devices between countries in Asia-Pacific…
Read more: Singapore >>
Focus on MEA
Saudi Arabia: SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey,…
MEA: Pfizer’s Saudi Transformation; Urgent Call for Arab…
The latest news from Middle East & North African pharma, including…
MEA: Iran looks to Cuba for COVID-19 Vaccine; Israel Leads…
The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region,…
5 Things to Know about Saudi Arabian Pharma
A rundown of five things to know about the USD 8.2 billion Saudi pharma market,…
Read more: MEA >>
Focus on Switzerland
Lonza Goes Big with Swiss Investments in Biologics, ADCs…
In the last month alone, CDMO giant Lonza has announced three major upgrades to…
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Ichnos CEO on Glenmark Legacy, Biotech Transformation &…
After an illustrious career in oncology R&D, contributing greatly to the…
Switzerland’s Quest for Alternatives to Animal Testing of…
Animal testing for medicinal purposes is back under the spotlight in Switzerland…
Read more: Switzerland >>
Focus on Europe
Switzerland Biotech Listing Snapshot 2021
The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI)…
Spanish Pharma News: Market Growth; Esteve’s US Expansion;…
The latest from Spanish pharma, including the acquisition of PTS by a private…
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Switzerland: A Sea Change in the Biotech Start-up Ecosystem?
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine…
Read more: Europe >>
Focus on Vaccines
Lonza Goes Big with Swiss Investments in Biologics, ADCs…
In the last month alone, CDMO giant Lonza has announced three major upgrades to…
Moderna: Bullish Bancel “Not Losing Sleep” over COVID-19…
The day the Biden administration announced its support for the waiver of IP…
Vaccine Wars: What the EU/AstraZeneca Row Shows Us About…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and…
US U-Turn as Biden Pledges Support for Waiver on COVID-19…
In a shock move, Joe Biden’s administration looks set to support a waiver on…